CTOR Citius Oncology Inc.

Price (delayed)

$1.01

Market cap

$93.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.47

Enterprise value

$87.56M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 17

Citius Oncology, Inc. is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults ...

Highlights
The revenue rose by 27% since the previous quarter
The company's equity rose by 25% YoY and by 15% QoQ
The debt has soared by 169% from the previous quarter and by 169% YoY
The net income has dropped by 73% year-on-year and by 8% since the previous quarter

Key stats

What are the main financial stats of CTOR

CTOR stock price

How has the Citius Oncology stock price performed over time
Intraday
-5.61%
1 week
5.89%
1 month
35.79%
1 year
-44.2%
YTD
1%
QTD
55.36%

Financial performance

How have Citius Oncology's revenue and profit performed over time
Revenue
$7.11M
Gross profit
$5.5M
Operating income
-$47.29M
Net income
-$46.06M
Gross margin
77.3%
Net margin
-648.3%
The company's operating income has shrunk by 86% YoY and by 9% QoQ
The net income has dropped by 73% year-on-year and by 8% since the previous quarter
The revenue rose by 27% since the previous quarter
The company's gross profit rose by 22% QoQ

Price vs fundamentals

How does CTOR's price correlate with its fundamentals

Growth

What is Citius Oncology's growth rate over time

Valuation

What is Citius Oncology stock price valuation
P/E
N/A
P/B
2.33
P/S
15.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.32
The EPS has contracted by 24% YoY
The company's equity rose by 25% YoY and by 15% QoQ
The P/B is 23% above the last 4 quarters average of 2.0
The revenue rose by 27% since the previous quarter

Efficiency

How efficient is Citius Oncology business performance
Citius Oncology's ROIC has plunged by 71% YoY and by 7% from the previous quarter
CTOR's ROE has shrunk by 51% YoY and by 3.5% QoQ
The ROA has contracted by 46% YoY and by 3.1% from the previous quarter
The ROS has grown by 14% from the previous quarter

Dividends

What is CTOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTOR.

Financial health

How did Citius Oncology financials performed over time
The total assets is 56% greater than the total liabilities
The current ratio has soared by 109% YoY and by 46% from the previous quarter
The total assets rose by 22% year-on-year and by 11% since the previous quarter
The debt is 75% less than the equity
The debt has soared by 169% from the previous quarter and by 169% YoY
The company's debt to equity has surged by 127% QoQ and by 108% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.